HtrA2/Omi is a mitochondrial serine protease that is released into the cytosol and promotes apoptotic processes by binding to several members of the inhibitors of apoptosis protein family. HtrA2/Omi knockout mice show a parkinsonian phenotype, and mutations in the gene encoding HtrA2/Omi have been identified as susceptibility factors for Parkinson disease (PD). These results suggest that HtrA2/ Omi may be involved in the pathogenesis of PD. We performed immunohistochemical studies of HtrA2/Omi on brains from patients with >-synuclein-related disorders, including PD, dementia with Lewy bodies (DLB), and multiple-system atrophy (MSA); patients with other neurodegenerative diseases; and controls. HtrA2/Omi is expressed in normal brain tissue, and there was some anti-HtrA2/ Omi immunostaining of neurons in normal brains as well as those with other neurodegenerative diseases. In PD and DLB brains, both classic (i.e. brainstem-type) and cortical Lewy bodies were intensely immunostained; pale bodies were also strongly immunopositive for HtrA2/Omi. In MSA brains, numerous glial cytoplasmic inclusions, neuronal cytoplasmic inclusions, and dystrophic neurites were also intensely immunoreactive for HtrA2/Omi. These results suggest that widespread accumulation of HtrA2/Omi may occur in pathologic >-synuclein-containing inclusions in brains with PD, DLB, or MSA and that HtrA2/Omi may be associated with the pathogenesis of >-synucleinopathies.
INTRODUCTION
Missense mutations of the >-synuclein gene (PARK1) (1Y3) and multiplications of the >-synuclein gene (PARK4) (4Y6) have been reported to be implicated in autosomal dominant familial forms of Parkinson disease (PD). Lewy bodies (LBs) are neuronal inclusions characteristic for PD and dementia with LBs (DLB) (7Y9), and >-synuclein has been confirmed to be a major constituent of LBs in PD and DLB (10Y12). Multiple-system atrophy (MSA) is a single nosologic entity that encompasses olivopontocerebellar atrophy, striatonigral degeneration, and Shy-Drager syndrome (13) . Specific oligodendroglial cytoplasmic inclusions, referred to as glial cytoplasmic inclusions (GCIs), are the major pathologic features of brains with MSA (14, 15) . >-Synuclein is also a major component of GCIs (12, 16, 17) . Therefore, PD, DLB, and MSA are now collectively referred to as >-synucleinopathies (18) .
The inhibitor of apoptosis protein (IAPs) play an important role in regulating apoptosis; some IAP family proteins, such as X chromosome-linked IAP, have the ability to bind to and directly inhibit selected caspases (19Y21). HtrA2/ Omi was identified as a mitochondrial serine protease that interacts with IAPs and contributes to the progression of apoptosis (22Y25). HtrA2/Omi is released from the mitochondrial intermembrane space into the cytosol upon receiving various apoptotic stimuli, and this released HtrA2/Omi induces apoptotic cell death by binding to IAPs, including X chromosome-linked IAP, and blocking their caspase-inhibitory activities (22Y27). HtrA2/Omi also enhances caspase activity by inducing permeabilization of the mitochondrial outer membrane, which leads to the release of cytochrome c (28) . Furthermore, HtrA2/Omi knockout mice were reported to show a parkinsonian phenotype, with selective neuronal loss in the striatum (29) . Together, these data suggest that, like cytochrome c, HtrA2/Omi is important for cell survival within the mitochondria and that, when it is released from the mitochondria, HtrA2/Omi promotes apoptotic cell death.
Recently, a G399S mutation of the HtrA2/Omi gene was identified in some patients with PD, and an A141S polymorphism of the HtrA2/Omi gene was also shown to be associated with PD. These data suggest that HtrA2/Omi is a susceptible factor for PD (PARK13 locus) (30) . The results from the targeted disruption of HtrA2/Omi in mice and a mutation screening for HtrA2/Omi in humans suggest that a loss of the function of HtrA2/Omi may be involved in the pathogenesis of PD, but the relationship between HtrA2/Omi and PD remains unclear. In the present study, we performed immunohistochemical studies on HtrA2/Omi using autopsied brains from patients with >-synucleinopathies, including PD. We investigated the detailed neuroanatomic localization of HtrA2/Omi in these diseased brains and found strong HtrA2/ Omi immunoreactivity in the >-synuclein-containing inclusions in PD, DLB, and MSA.
MATERIALS AND METHODS

Tissue Preparation
Brains from autopsies of 8 control subjects without any neurologic abnormalities (age range, 54Y78 years; mean, 68.4 years; 6 men and 2 women), 10 patients with PD (age range, 66Y90 years; mean, 77.5 years; 6 men and 4 women), 5 patients with DLB (age range, 69Y86 years; mean, 74.8 years; 4 men and 1 woman), 10 patients with MSA (age range, 52Y78 years; mean, 69.1 years; 4 men and 6 women), 5 patients with Alzheimer disease (AD) (age range, 67Y85 years; mean, 75.2 years; 1 man and 4 women), a patient with frontotemporal dementia with parkinsonism linked to chromosome 17 (54-year-old man), and a patient with frontotemporal lobar degeneration with ubiquitin-positive inclusions (66-year-old woman). These materials were selected from the brain banks at the Neuropathology Laboratories of Kyoto University and Medical University of Vienna. In 5 of 10 patients with MSA, the MSA was classified as cerebellar variant, and in the other 5 patients, MSA of the parkinsonian variant. The clinical profiles from all cases are summarized in Table 1 . All brains were fixed in 10% neutral formalin for about 2 weeks at room temperature. Several paraffin-embedded tissue blocks, including the frontal and temporal cortices, basal ganglia, brainstem, and cerebellum, were prepared and cut into 6-Km-thick sections on a microtome. Sections were deparaffinized in xylene, followed by rehydration in a decreasing concentration of ethanol solutions. For routine pathologic evaluation, the sections from all cases were stained with hematoxylin and eosin (H&E), Klüver-Barrera, and modified Bielschowsky methods. No histologic abnormalities were detected in the sections from any of the control cases. A loss of dopaminergic neurons associated with the presence of classic (brainstem-type) LBs was observed in the substantia nigra from both PD and DLB cases. In addition, many cortical LBs were found in the cerebral cortical regions of the DLB cases, and diagnoses of DLB cases were made according to revised criteria (31) . Numerous GCIs were detected in the sections from all of the MSA cases.
Immunohistochemistry
To examine the immunohistochemical localization of HtrA2/Omi, we used an anti-HtrA2/Omi anti-serum raised by immunizing rabbits with Escherichia coli expressing the C-terminal His 6 -tagged mature form of human HtrA2/Omi protein (22) . The deparaffinized sections were pretreated with 0.3% hydrogen peroxide (Santoku, Tokyo, Japan) in After washing with 0.1 M PBS, the sections were blocked with 0.1 M PBS with 3% skim milk for 2 hours at room temperature. After rinsing with 0.1 M PBS, the anti-HtrA2/ Omi anti-serum diluted in 0.1 M PBS (1:200) was applied onto the sections, and they were incubated at room temperature overnight in a humidified chamber. After washing with 0.1 M PBS, the sections were reacted with a biotinylated antirabbit immunoglobulin G (IgG; Vector Laboratories, Burlingame, CA) diluted in 0.1 M PBS (1:200) for 1 hour at room temperature, followed by incubation with an avidin-biotinperoxidase complex (ABC) kit (Vector Laboratories) diluted in 0.1 M PBS (1:400) for 1 hour at room temperature. After rinsing with 0.1 M PBS and then 0.05 M Tris-HCl (pH 7.6), the sections were developed in a colorizing solution containing 0.02% diaminobenzidine tetrahydrochloride (Dojin, Kumamoto, Japan), 0.6% ammonium nickel (II) sulfate (Wako, Osaka, Japan), and 0.005% hydrogen peroxide in 0.05 M Tris-HCl (pH 7.6) for 10 minutes at room temperature. Some H&E-stained sections with classic or cortical LBs were photographed, decolorized with 70% ethanol and were then immunostained with the anti-HtrA2/Omi antiserum using the ABC method described above. As a negative immunohistochemical control, some sections were incubated with a preimmune rabbit serum; no specific staining was detected in these control sections (data not shown).
Double Immunofluorescence Staining
To compare the anatomic distribution of >-synucleinimmunopositive inclusions to that of HtrA2/Omiimmunopositive inclusions in brains with >-synucleinopathies, we performed double-labeling immunohistochemistry using a goat polyclonal anti->-synuclein antibody (sc-7011; Santa Cruz Biotechnology, Santa Cruz, CA) and the rabbit antiHtrA2/Omi anti-serum. Some sections from the PD, DLB, and MSA cases were incubated with the combination of the anti->-synuclein antibody (1:1000) plus the anti-HtrA2/Omi antiserum (1:200) in 0.1 M PBS at room temperature overnight. After washing with 0.01 M PBS, the sections were reacted with secondary antibodies consisting of a tetramethylrhodamineconjugated swine anti-rabbit IgG (DakoCytomation, Glostrup, Denmark) and a fluorescein isothiocyanate-conjugated swine anti-goat IgG (Biosource, Camarillo, CA). After rinsing with 0.01 M PBS, the slides were coverslipped with Vectashield (Vector Laboratories) and were then viewed with a fluorescence microscope system (BZ-9000, Keyence, Osaka, Japan).
Semiquantitative Assessment of HtrA2/ Omi-Immunopositive LBs and GCIs
To evaluate the proportions of HtrA2/Omiimmunopositive classic LBs in the substantia nigra, locus ceruleus, dorsal motor nucleus of the vagus, and basal nucleus of Meynert, we prepared several kinds of sections doubleimmunostained with >-synuclein and HtrA2/Omi from all 10 PD cases. After counting the >-synuclein-immunopositive classic LBs in these areas, we counted the double-immunolabeled classic LBs in the same areas. We then calculated the percentage of HtrA2/Omi-immunopositive classic LBs in each section and the average percentages of HtrA2/Omi-positive classic LBs in the substantia nigra, locus ceruleus, dorsal motor nucleus of the vagus, and basal nucleus of Meynert.
To estimate the proportions of HtrA2/Omiimmunopositive cortical LBs in DLB and GCIs in MSA, we prepared double-immunostained sections with >-synuclein and HtrA2/Omi from all of the DLB and MSA cases. Using the same counting method, we calculated the average percentages of HtrA2/Omi-positive cortical LBs in the superior frontal, cingulate, insular, and parahippocampal cortices and the average percentages of HtrA2/Omi-positive GCIs in the internal capsule, putamen, middle cerebellar peduncle, and cerebellar white matter.
Characterization of the Primary Anti-Serum
The specificity of the anti-HtrA2/Omi anti-serum was confirmed by Western blotting using human brain homogenates. Fresh brain tissues were obtained from the frontal cortex of an autopsied normal subject (68-year-old man). These materials were homogenized in 3 volumes of ice-cold 10 mM PBS containing 1% Nonidet P-40 (Nacalai Tesque, Kyoto, Japan), 0.5% sodium deoxycholate (Difco, Detroit, MI), 0.1% sodium dodecyl sulfate (SDS; Nacalai Tesque), 0.01% phenylmethylsulfonyl fluoride (Nacalai Tesque), 3% aprotinin (Sigma, St Louis, MO), and 1 mM sodium orthovanadate (Sigma). The homogenates were then centrifuged at 15,000 revolutions per minute (r.p.m.) for 15 minutes at 4-C, and the supernatants were then mixed with an equivalent volume of electrophoresis sample buffer containing 10% glycerol (Nacalai Tesque), 2% SDS, 5% 2-mercaptoethanol (Nacalai Tesque), and 0.00125% bromophenol blue (Nacalai Tesque) in 62.5 mM Tris-HCl (pH 6.8). All samples were then heated for 3 minutes at 100-C and then cooled to room temperature. A 10-KL aliquot of the sample was loaded onto each lane of Mini-Protean II Ready Gels J (Bio-Rad, Hercules, CA), electrophoresed at a constant voltage of 200 V, and then transferred onto polyvinylidene diflouride membranes (Bio-Rad) at a constant voltage of 100 V. After blocking the nonspecific reactions with 3% skim milk plus normal goat serum in 25 mM Tris-buffered saline (TBS), the membranes were incubated with the anti-HtrA2/ Omi serum (1:5000) or preimmune serum (1:5000) in 25 mM TBS plus 3% skim milk for 4 hours at room temperature. After washing with 25 mM TBS containing 0.1% Tween 20 (Bio-Rad), the membranes were reacted with an alkaline phosphatase-labeled anti-rabbit IgG (Vector, 1:1000) in 25 mM TBS with 3% skim milk for 1 hour at room temperature. After rinsing with 25 mM TBS containing 0.1% Tween 20, the primary antibodies were visualized using a 5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium kit (Nacalai Tesque).
We also performed immunohistochemical studies on HtrA2/Omi using HtrA2/Omi knockout mouse brain sections as a negative control. Brain tissues of knockout and wild-type control mice (both of which have been previously described [29] ) were fixed in 10% neutral formalin, stored in 20% sucrose in 0.1 M phosphate buffer, and then cut into 20-Kmthick sections on a freezing microtome. Free-floating sections were immunostained with the anti-HtrA2/Omi serum (1:5000) using the ABC method described above.
Brain Tissue Fractionation
Human brain homogenates were divided into 3 fractions based on their solubility in PBS, SDS, and formic acid. Fresh frontal cortical tissue samples from a control subject (68-year-old man) and a patient with DLB (77-year-old man) were homogenized in 3 volumes of ice-cold 10 mM PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.01% phenylmethylsulfonyl fluoride, 3% aprotinin, and 1 mM sodium orthovanadate. Each homogenate was centrifuged at 2,500 r.p.m. for 10 minutes at 4-C, and the supernatant was subsequently centrifuged at 55,000 r.p.m. for 1 hour at 4-C, yielding the supernatant (S1, PBSsoluble fraction) and pellet (P1). After washing with 10 mM PBS containing same additives (Buffer A), the P1 pellet was extracted with Buffer A containing 2% SDS and then centrifuged at 55,000 r.p.m. for 1 hour at 4-C, yielding the supernatant (S2, SDS-soluble fraction) and pellet (P2). After rinsing with Buffer A, the P2 pellet was extracted 70% formic acid and then centrifuged at 55,000 r.p.m. for 1 hour at 4-C. The formic acid extract was dried, and the residue was dissolved in Buffer A (S3, formic acid-soluble fraction). All fractions were analyzed using Western blotting with the antiHtrA2/Omi anti-serum as described above.
RESULTS
Western Blot Analysis
In normal human brain homogenates, the anti-HtrA2/ Omi anti-serum immunostained a single band at a molecular weight of approximately 36 kd (Fig. 1A) . This corresponds to the molecular weight of the mature form of human HtrA2/ Omi and indicates that the anti-serum recognizes HtrA2/Omi in human brain tissues. No specific immunopositive bands were detected in the membrane incubated with the preimmune serum (Fig. 1A) . HtrA2/Omi immunoreactivity was detected in the S1 and S2 fractions from control and DLB brains, but the S3 fractions from both showed no HtrA2/Omi immunoreactivity on Western blot (Fig. 2) .
HtrA2/Omi Immunoreactivities in Normal and Knockout Mice Brains
HtrA2/Omi immunoreactivity was observed in several types of neurons in the wild-type control mouse brain sections (Fig. 1B) , but no specific immunopositive staining was found in the knockout mouse brain sections (Fig. 1C) .
HtrA2/Omi Immunoreactivities in Normal and PD Brains
In the substantia nigra of control subjects, melanincontaining neurons generally showed mild to moderate HtrA2/Omi immunoreactivity (Fig. 3A) . A similar immunolabeling pattern was observed in the remaining neurons of the substantia nigra from patients with PD (Fig. 3B) .
Classic LBs, which generally consist of an eosinophilic core plus a surrounding pale halo (Figs. 3C, E) , had a ring-shaped HtrA2/Omi immunostaining pattern; dense accumulations of immunoreactive products were also found in the halos of these LBs (Figs. 3D, F) . Some remaining neurons contained 2 or more HtrA2/Omi-immunopositive LBs (Fig. 3G) . Pale bodies, which are well-defined, less eosinophilic structures (Fig. 3H) , were also heterogeneously immunolabeled (Fig. 3I) and had abundant granular HtrA2/ Omi immunoreactivity in their peripheries (Fig. 3I) . HtrA2/ Omi-immunopositive classic LBs were also found in neurons of the locus ceruleus, dorsal motor nucleus of the vagus, and nucleus basalis of Meynert (not shown).
HtrA2/Omi Immunoreactivities in Normal and DLB Brains
A similar immunolabeling pattern was observed in these regions in DLB patients, immunoreactivity was distributed densely throughout the somata of some remaining neurons (Fig. 4B) . Only a few Lewy neurites were immunopositive for HtrA2/Omi (Fig. 4C) .
Cortical LBs (i.e. ill-defined, eosinophilic inclusions without a conspicuous core and a clear halo [Figs. 4D, F , H]) were immunopositive for HtrA2/Omi (Figs. 4E, G, I ). Some cortical LBs were immunostained diffusely (Fig. 4E) , whereas others had partial immunostaining and strongly stained marginal zones (Fig. 4G) or central portions (Fig. 4I) . These immunopositive cortical LBs were found throughout the cerebral cortical areas but were more numerous in cingulate, insular, and parahippocampal cortices. As in PD patients, the halos of classic LBs were intensely immunolabeled in DLB patients (not shown).
HtrA2/Omi Immunoreactivities in Normal and MSA Brains
Cerebellar Purkinje cells were mildly to moderately immunostained both in normal subjects (Fig. 5A ) and in patients with MSA (Fig. 5B) . The torpedoes, which were observed more often in the MSA cases, were also strongly immunopositive for HtrA2/Omi (Fig. 5C ). Neuronal labeling patterns in substantia nigra, pontine nuclei, inferior olivary nucleus, and striatum in MSA patients were similar to those in the normal controls.
Glial cytoplasmic inclusions in the basis pontis (Fig. 5D ), middle cerebellar peduncle, cerebellar white matter (Fig. 5E) , putamen (Fig. 5F ), and internal capsule were immunopositive in MSA patients. Strongly immunopositive neuronal cytoplasmic inclusions (NCIs) were found in some remaining neurons of the pons (Figs. 5G, H ) and inferior olivary nucleus; a few dystrophic neurites were also densely immunopositive for HtrA2/Omi in various areas, including the basis pontis and thalamus (Fig. 5I ). There were no significant differences in the immunolabeling patterns between the cases with MSA of cerebellar variant and of parkinsonian variant.
Double-Labeling Immunohistochemistry for HtrA2/Omi and >-Synuclein
Double-immunostained sections demonstrated HtrA2/ Omi and >-synuclein colocalization in many classic LBs (Figs. 6AYC), cortical LBs (Figs. 6DYF) , and GCIs (Figs. 6GYI) . The colocalization of HtrA2/Omi and >-synuclein was also observed in some NCIs (Figs. 6JYL) . Semiquantitative data on percentages of HtrA2/Omi-immunopositive LBs and GCIs are summarized in Table 2 . 
HtrA2/Omi Immunoreactivities in Brains With Other Diseases
HtrA2/Omi immunoreactivity was also observed in some neurofibrillary tangles (Fig. 7A ) and dystrophic neurites of senile plaques (Fig. 7B) in the brains of patients with AD. By contrast, neuronal and glial inclusions in the case with frontotemporal dementia with parkinsonism linked to chromosome 17 and the case with frontotemporal lobar degeneration with ubiquitin-positive inclusions were immunonegative for HtrA2/Omi.
DISCUSSION
We demonstrate the widespread accumulation of HtrA2/Omi in >-synuclein-containing inclusions in the brains of patients with several types of >-synucleinopathies. To the best of our knowledge, this is the first detailed distribution of HtrA2/Omi immunoreactivity in the brains of these patients. In their study of mutations in the HtrA2/Omi gene, Strauss and colleagues (30) referred to the immunohistochemical localization of HtrA2/Omi in classic LBs. We also observed HtrA2/Omi immunoreactivity in the halos of classic LBs and demonstrated HtrA2/Omi immunoreactivity in cortical LBs and pale bodies in patients with PD and DLB, and in GCIs and NCIs in patients with MSA.
Both pale bodies and classic LBs are found in the pigmented neurons of the substantia nigra in patients with PD. Because pale bodies are generally considered to be precursors of classic LBs (9, 32) , and both are immunopositive for >-synuclein (9, 12) , the presence of HtrA2/Omi as well as of >-synuclein suggests that both may be involved in the formation of classic LBs in the early stages. The immunostaining of pale bodies was heterogeneous, but immunoreaction product was predominantly distributed at their margins. Because the halos of the classic LBs were densely immunopositive, these observations suggest that HtrA2/Omi may accumulate toward the marginal zones of the pale bodies and subsequently form the halos of classic LBs.
Cortical LBs were also immunopositive for HtrA2/ Omi, but unlike classic LBs, most cortical LBs did not exhibit a ring-shaped labeling pattern. Some cortical LBs were immunostained diffusely, but HtrA2/Omi immunoreactivity was located mainly at their margins or central portions. Cortical LBs are usually poorly defined eosinophilic structures, and the central cores and peripheral halos usually observed in classic LBs are not evident (8, 9) . These differences in structure may contribute to the different HtrA2/ Omi-immunostaining patterns.
Since the discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine could cause PD-like symptoms in humans (33) , several studies have shown that mitochondrial dysfunction plays an important role in the pathogenesis of PD (34) . For example, the gene encoding PTEN-induced putative kinase 1 (PINK1) is responsible for PARK6-associated autosomal recessive juvenile parkinsonism (35) , and PINK1 has been reported to be localized in the mitochondria (36, 37) . Although the immunohistochemical localization of PINK1 in GCIs is controversial (37, 38) , PINK1 immunoreactivity has also been found in LBs (37, 38) . Recently, HtrA2/Omi was reported to be phosphorylated in a PINK1-dependent manner (39) . Because in the present study, we demonstrate the mitochondria-related protein HtrA2/Omi in LBs, interactions between PINK1 and HtrA2/Omi may occur in LBs, and together they may be involved in LB formation.
Mitochondrial dysfunction can lead to apoptotic cell death. There is both neuronal apoptosis in the substantia nigra of patients with PD (40) and oligodendrocyte apoptosis in oligodendrocytes in the brains of patients with MSA (41) . Some surviving dopaminergic neurons contain classic LBs in PD (8, 9) , and many surviving oligodendrocytes harbor GCIs in MSA (14, 15) . Whether these cytoplasmic inclusions induce apoptotic cell death or are protective of these cells from the toxic effects of misfolded proteins remains controversial, but several lines of evidence support the hypothesis that the formation of >-synuclein-containing inclusions may be cytoprotective (42, 43) . In the present study, we found that both LBs and GCIs contained dense immunoreactivity for HtrA2/Omi, which in the cytosol might promote apoptosis. Based on these data, we suggest that these inclusions may trap HtrA2/Omi that has been released from the mitochondria and thus protect the dopaminergic neurons in PD and the oligodendrocytes in MSA from HtrA2/Omi-related apoptotic cell death.
A widespread distribution of GCIs in the central nervous system is the main pathologic feature of patients with MSA (14, 15, 44) , and >-synuclein is a major component of GCIs (12, 16, 17) , but the primary cause of MSA is still undetermined. The intense HtrA2/Omi immunoreactivity observed in GCIs as well as in NCIs and dystrophic neurites in the brains of patients with MSA in the present study suggests that HtrA2/Omi accumulates widely in MSA and that it may be one of the key proteins involved in MSA pathogenesis. Multiple-system atrophy is generally considered to be a sporadic disease, and although familial MSA cases have been identified (45) , the genetic factors responsible for MSA remain unclear. Recently, null mutations in the HtrA2/Omi gene in mice were shown to lead to parkinsonism accompanied by striatal degeneration (29) , a characteristic feature of MSA. Taken together, these results support the possibility that mutations of the gene encoding HtrA2/Omi could be involved in the pathogenesis of MSA. Further genetic analyses on HtrA2/Omi in patients with MSA are necessary.
In conclusion, we found that HtrA2/Omi immunoreactivity accumulated abundantly in brains with >-synucleinopathies, particularly in several types of inclusions containing insoluble >-synuclein, suggesting that HtrA2/Omi may be involved in the aggregation of >-synuclein. Several recent studies have shown that HtrA2/Omi plays an important role in the pathogenesis of AD by regulating A-amyloid precursor protein metabolism (46Y48). We also observed the localization of HtrA2/Omi immunoreactivity in some inclusions in brains from patients with AD. These data suggest that HtrA2/Omi may be associated with the pathogenesis of a wide spectrum of neurodegenerative disorders, and further research on the interactions of HtrA2/Omi with >-synuclein will provide new insights into the pathologic mechanisms responsible for >-synucleinopathies.
